Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Panretin trial in KS halted early

Aug. 29, 1997

Notice of allowance for LHRH vaccine patent

Aug. 29, 1997

ImmunoGen's apoptosis research receives patent protection

Aug. 28, 1997

Phase II trials of ISIS-3521 begin

Aug. 27, 1997

U.S. patent issued for CEP-2563

Aug. 27, 1997

Antineoplastic peptides from BASF

Aug. 26, 1997

Targeted Genetics receives patent protection for tgDCC-E1A

Aug. 26, 1997

Microtubule inhibitor with low toxicity and unique profile of CaM activity

Aug. 25, 1997

Apoptosis modulators reported in patent literature

Aug. 22, 1997

Telomerase-inhibitory oligonucleotides for treating cancer

Aug. 22, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....